Dyve Biosciences’ transdermal gout treatment
Dyve Biosciences CEO Ryan Beal told Drug Delivery Business News in a 2019 interview that there haven’t been enough innovations in treatment for acute gout pain.
Patients often deal with pain for days, but the Thousand Oaks, Calif.-based company’s DYV-700 transdermal treatment seeks to turn that into mere minutes.
The company develops its therapeutic in the form of a topical cream with the consistency of a moisturizer or lotion. The patient is supposed to apply it to the limb of the affected joint three times per day and the drug is designed to penetrate the skin, get into the joint space and change the pH environment in the joint, dissolving the crystals that cause pain.
A pilot study revealed a nearly 50% reduction in gout attack duration as meaningful and significant pain reduction was observed in minutes, not days.
More R&D is being conducted to see what other conditions may be treated with Dyve’s transdermal therapeutic, but for now the company is focused on gout and melasma, which is hormone-induced hyper-pigmentation during pregnancy.
